|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Supplementary table 1: Completed phase 3 clinical trials on immunotherapy for patient with advanced or metastatic renal cell carcinoma** | | | | | | | | |
| **Line of therapy** | **Agent** | **Trial name** | **Inclusion criteria** | **Number of patients** | **Objective response rate (%)** | **Complete response and partial response (%)** | **Median progression free survival (months)** | **Adverse events (%)** |
| Not first | **Nivolumab  vs  Everolimus** | CheckMate 025 | Patients with advanced or metastatic ccRCC histologically confirmed | 821 | 25 vs 5 | 1/24  vs  1/5 | 5 vs 4 | Grade 3-4=  19 vs 37 |
| First | **Nivolumab**  **+**  **Ipilimubab**  **vs**  **Sunitinib** | CheckMate 214 | Patients with advanced or metastatic ccRCC histologically confirmed | 1096 | Intermediate/poor risk  42 vs 27 | 9/32  vs  1/25 | Intermediate/poor risk  12 vs 8 | Grade 3-4  46 vs 63 |
| **Atezolizumab + Bevacizumab  vs  Sunitinib** | IMmotion  151 | Unresectable locally advanced or metastatic ccRCC with or without sarcomatoid feature | 915 | Intent to treat  37 vs 33  Intent to treat with PD-L1 > 1%  43 vs 35 | - | Intent to treat  11 vs 8  Intent to treat with PD-L1>1%  11 vs 8 | Grade 2-4  40 vs 54 |